Few months in recent memory have delivered as many first-ever treatments. In September, the FDA approved first therapies for Alexander disease, Sanfilippo syndrome type A and MCT8 deficiency, added a third option for FOP, and approved a new therapy in SMA. Ultragenyx’s Fayuvi, priced at $3.95M, became the company’s second gene therapy approval in the past month.
Beacon Therapeutics also delivered a pivotal gene therapy win in X-linked retinitis pigmentosa, a disease where larger players had previously failed. But September was also a month of contrasts: Ultragenyx’s Phase 3 in Angelman syndrome failed two weeks before Fayuvi’s approval, while Novartis faced a Phase 3 miss in myotonic dystrophy type 1 and stopped its TREM2 program in ALS.
In Huntington’s disease, uniQure filed AMT-130, but its four-year data were no longer statistically significant on the composite cUHDRS endpoint versus an external natural-history cohort, a reminder of how hard it is to demonstrate benefit in slowly progressive neurological diseases.
On the capital side, investors kept backing genetic medicine: Encoded closed a $275M Series F to take its Dravet syndrome program through pivotal development, while Novartis paid $125M for a blood–brain barrier crossing platform. Capital continues to flow to programs approaching decisive milestones, and CNS delivery remains a strategic priority.
1. Clinical news & patient access
September 2026 confirms that rare-disease drug development remains highly attractive, with unprecedented regulatory support for genetically defined diseases, but clinical risk in CNS disorders remains substantial and target validation matters far more than therapeutic modality.
Sep 3, 2026 — Ultragenyx’s Apazunersen Fails Phase 3 Aspire Trial in Angelman Syndrome
Ultragenyx reported that its Phase 3 Aspire trial of apazunersen in Angelman syndrome, a rare genetic disorder of the nervous system causing severe physical and learning disabilities, did not meet its primary endpoint, the change from baseline in Bayley-4 cognitive raw score. The trial also missed its secondary endpoint, the Multidomain Responder Index, a measure of clinical function. The company did not disclose detailed figures. Shares fell 43% after hours, and Ultragenyx said it is reviewing the future of the program and plans significant expense reductions, after already cutting 10% of its workforce in February. The setback came just two weeks after the accelerated approval of its gene therapy Genglycos in GSDIa, and is a reminder that strong early-phase data in neurodevelopmental disorders do not always translate into pivotal success.
The FDA approved Zanvastro (zilganersen), developed by Ionis based on research from the University of Wisconsin–Madison, as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive and often fatal neurological disorder affecting fewer than one in a million people. Zanvastro is an antisense oligonucleotide (ASO) that directly targets GFAP, the protein whose toxic accumulation in astrocytes drives the disease. The application was supported by a Phase 1–3 study in 54 participants aged 1.5 to 53 years, most of them children, which met its primary endpoint on functional mobility (10-Meter Walk Test) versus placebo. Treated patients showed stabilisation and, in some cases, improvement of motor function. Until now, care had been limited to symptom management.
Sep 8, 2026 — Novartis’ Del-desiran Fails Phase 3 HARBOR Trial in Myotonic Dystrophy Type 1
Novartis reported that del-desiran failed its pivotal Phase 3 HARBOR trial in myotonic dystrophy type 1 (DM1), a rare neuromuscular disease causing progressive muscle stiffness and weakness. The drug did not outperform placebo on the primary endpoint, video hand opening time (vHOT), which measures how well the hand relaxes after squeezing. It was Novartis’ second major trial failure in a matter of days, after a cardiovascular study, and the stock fell by as much as 10% in early trading in Switzerland. The result adds pressure on Novartis’ pipeline and acquisition strategy as it approaches a major patent cliff.
Scholar Rock received FDA approval of Isembyld (apitegromab) for spinal muscular atrophy (SMA) on September 11, ahead of its September 30 target action date. Isembyld is a muscle-targeted monoclonal antibody built on Scholar Rock’s myostatin biology platform, given by intravenous infusion every four weeks. Unlike existing SMN2-targeted therapies, which keep motor neurons alive, Isembyld is the first therapy to directly address muscle loss and is used on top of SMN2-targeted treatment, in adults and children aged 2 and older. In the Phase 3 SAPPHIRE trial, patients on Isembyld improved motor function by 2.2 points on the HFMSE versus placebo after one year, while patients on SMN2-targeted therapy alone declined.
Sep 16, 2026 — Novartis Ends ALS Program After Phase 2 Failure of VHB937
Novartis stopped development of VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the Phase 2 ASTRALS trial in 251 patients with early-stage ALS missed both its primary and secondary endpoints. VHB937 is designed to stabilise and activate TREM2, a protein that could make microglia, the brain’s immune cells, protect motor neurons. A Phase 2 trial in Alzheimer’s disease is still enrolling. The failure adds to the poor clinical track record of TREM2-targeting drugs, after setbacks for Alector in 2024 and Vigil Neuroscience last year.
Ultragenyx received FDA approval of Fayuvi (UX111) for children with mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A), an inherited neurological disease caused by sulfamidase deficiency, leading to heparan sulfate accumulation and central nervous system damage, typically fatal in the teenage years. Fayuvi is a one-time intravenous gene therapy using an engineered virus to deliver a functional copy of the SGSH gene. It is indicated for children with preserved neurodevelopmental function. Approval was based on an open-label, single-arm study in which treated children aged 2 to 5 maintained or improved cognitive scores versus natural history. It is Ultragenyx’s second gene therapy approval, coming just two weeks after the Phase 3 failure of apazunersen in Angelman syndrome. Ultragenyx also received a Priority Review Voucher with the approval.
Beacon Therapeutics reported positive results from its pivotal Phase 2/3 VISTA trial of laruparetigene zovaparvovec (laru-zova), a gene therapy for X-linked retinitis pigmentosa (XLRP), a rare inherited disease causing progressive vision loss that mainly affects men and boys. The trial tested two doses in 85 patients. At 12 months, 24.1% of patients on the low dose and 31% on the high dose were responders, defined as reading at least 15 more letters on an eye chart in low light, compared with none in the control group, meeting the primary endpoint. The result stands out because Biogen’s Phase 2/3 trial in XLRP failed in 2021 and J&J suffered a Phase 3 setback last year. Beacon plans to start a rolling BLA submission to the FDA before year-end and to seek approval in the EU and the UK, possibly with partners.
Mirum Pharmaceuticals, which licensed the drug from Incyte in April, received FDA approval of Atebrioz for FOP, an ultra-rare genetic disease in which muscles, tendons and ligaments progressively turn into bone. Atebrioz is a once-daily oral ALK2 inhibitor indicated for adults and children aged 12 and older. Approval was based on a randomized, double-blind, placebo-controlled trial in 63 patients, in which patients on Atebrioz showed an average 3.2 cm³ decrease in the volume of new heterotopic bone at Week 24, versus a 24.6 cm³ increase on placebo. Atebrioz is the third FOP therapy, after Ipsen’s Sohonos and Regeneron’s Pasatru, approved in August.
Swedish biotech Egetis received FDA approval of Emcitate for peripheral thyrotoxicosis in MCT8 deficiency (Allan–Herndon–Dudley syndrome), a life-limiting X-linked disorder caused by SLC16A2 mutations that impair thyroid hormone transport, including into the brain. Emcitate is a thyroid hormone receptor agonist indicated for adults and pediatric patients and is the first FDA-approved treatment for this disease in the United States. The approval was supported by a program including the ReTRIACt and Triac trials, Erasmus MC cohort studies and a U.S. expanded access program. Egetis also received a Rare Pediatric Disease Priority Review Voucher.
Sep 29, 2026 — uniQure Files BLA for AMT-130 in Huntington’s Disease, with Mixed Four-Year Data
uniQure submitted a BLA to the FDA for AMT-130 (ifezuntirgene inilparvovec), an investigational gene therapy for Huntington’s disease, with an acceptance decision expected in Q4; its U.K. marketing application has also been validated. At 36 months, high-dose patients showed an 80% slowing of cUHDRS decline and a 67% slowing on Total Functional Capacity (TFC) versus a matched external ENROLL-HD natural-history cohort. At 48 months (first 12 high-dose patients), a 61% slowing in TFC decline was observed, but the cUHDRS result was not statistically significant in the updated comparison. The therapy was generally well tolerated, and uniQure plans to begin screening for a confirmatory study before year-end, with TFC as planned primary endpoint.
Patient access news
Europe
The European Commission granted marketing authorisation under exceptional circumstances to Nezglyal (leriglitazone) for cerebral adrenoleukodystrophy (cALD) in male patients aged 2 to 12 years with gadolinium-negative brain lesions. The decision follows the positive CHMP opinion of July 23, covered in our July-August edition.
United States
Sep 17, 2026 — Ultragenyx Sets $3.95M U.S. List Price for Fayuvi
Ultragenyx set a $3.95 million U.S. list price for its one-time Sanfilippo gene therapy, among the most expensive drugs in the world, arguing that lifetime care costs can exceed $8 million. The therapy is expected to be available at specialised U.S. treatment centres within 30 to 60 days.
Sep 25, 2026 — Mirum Launches Atebrioz Through Mirum Access Plus Program
Mirum expects Atebrioz to be available in the United States in October through its Mirum Access Plus (MAP) program, with eligible patients paying as little as $0 per month.
Sep 28, 2026 — Egetis Launches Egetis RareLink Patient Support Program for Emcitate
Alongside approval, Egetis launched Egetis RareLink, its patient support program for Emcitate, in partnership with PANTHERx Rare.
2. Financings & Partnerships
The rare disease sector remains healthy and well-funded, but capital is becoming increasingly concentrated around genetically validated diseases, enabling technologies (delivery/editing/platforms), and programs that have already generated convincing human data.
Sep 3, 2026 — Typewriter Therapeutics Emerges from Stealth with $56M Series A
Deal: U.S. biotech Typewriter Therapeutics, which also runs a Japanese arm, launched with a $56M Series A to insert genes using RNA alone. The round was led by AN Venture Partners and RA Capital Management, with ANRI, Gemseki and SBI US Gateway Fund participating.
Type: Venture financing / Genetic medicine platform
Sep 9, 2026 — Encoded Therapeutics Raises $275M Series F to Advance ETX101 in Dravet Syndrome
Deal: Encoded Therapeutics closed a $275M Series F co-led by GV and another healthcare fund, with participation from ARCH Venture Partners, RTW Investments, SoftBank Vision Fund 2, Venrock and others. Proceeds fund the pivotal study of ETX101, a precision genetic medicine for infants and young children with SCN1A+ Dravet syndrome, following encouraging interim Phase 1/2 POLARIS data, plus an expansion study up to age 18, commercial scale-up of internal GMP manufacturing, and a 2027 IND for ETX301.
Type: Late-stage venture financing / CNS genetic medicine
Sep 16, 2026 — Novartis Pays $125M for Sironax’s Blood–Brain Barrier Crossing Platform
Deal: Novartis acquired global rights to a blood–brain barrier crossing technology developed by Sironax for $125M. Proceeds will help Sironax advance three candidates it describes as potentially best-in-class.
Type: Licensing / CNS delivery platform
Sep 17, 2026 — Lisata Therapeutics Acquires Marea Therapeutics
Deal: Lisata Therapeutics announced the acquisition of Marea Therapeutics, a U.S. biotech developing monoclonal antibodies in rare diseases. Financial terms were not disclosed.
Type: M&A / Rare disease
3. Research breakthroughs
Prime Assembly: Writing Gene-Sized DNA Into Precise Genomic Locations
A study published in Nature by researchers at Boston Children’s Hospital introduces prime assembly, a genome engineering method that stitches long DNA fragments — including one or more gene-sized pieces — into precise, programmable positions in living cells.
Building on prime editing, the approach writes a DNA “flap” on each genome strand to define exactly where the replacement starts and ends, then captures matching DNA inserts to create large, permanent edits. It does not rely on DNA double-strand breaks or double-strand donors, both of which can be toxic, and works in non-dividing cells.
The implication for rare diseases is significant: many genetic disorders involve hundreds of different mutations, each currently requiring its own edit. Prime assembly could correct almost any mutation in a gene with a single approach, pointing toward universal gene therapies usable across many patients.
Gene Editing Repairs the OTC Gene at Its Native Locus for a More Durable Liver Therapy in Children
Researchers at the Children’s Medical Research Institute (CMRI), publishing in Molecular Therapy, tackled a key limit of liver gene therapy in children: as the liver grows, cells carrying an added gene copy are progressively outnumbered by new untreated cells. Focusing on ornithine transcarbamylase (OTC) deficiency — a severe genetic liver disorder that prevents the body from properly breaking down waste products from protein digestion, caused by more than 500 different mutations — the team developed a mutation-agnostic genome-editing strategy that repairs the gene at its natural location. The approach efficiently repaired OTC in patient-derived human liver cells and laboratory models, preserved the liver’s normal pattern of OTC expression and corrected the metabolic defect, offering a potentially more durable option for very young patients.
Upcoming events
October 22–23, 2026 — 4th International Conference on Rare Diseases and Orphan Drugs 2026 — Barcelona, Spain
Global scientific conference themed “From Discovery to Cure: Transforming Rare Disease Care,” highlighting cutting-edge research, therapeutic innovation, and patient-centered care models.
October 25–27, 2026 — NORD Rare Diseases & Orphan Products Breakthrough Summit 2026 — Washington, DC, USA
October 26–28, 2026 — World Orphan Drug Congress Europe — Amsterdam, Netherlands
Leading global forum dedicated to rare disease drug development, orphan drug regulation, and market access, featuring stakeholders from biotech, pharma, patient advocacy groups, and regulators.
November 10–12, 2026 — BIO-Europe 2026 — Cologne, Germany
One of the largest global biotech partnering conferences, bringing together biopharma companies, investors, and rare disease developers to accelerate licensing deals and cross-border partnerships.